Parabilis’ US listing means the biotech IPO record has been broken twice in as many months as public listings continue hot ...

The new MHRA sandbox will allow innovators to test AI systems to enhance medicines’ safety and predict side effects.

The Cambridge, Massachusetts-based biotech priced 33.5 million shares at $20 each, topping the $625 million raised by Kailera ...

Parabilis Medicines priced its upsized IPO at $20 per share, raising $670 million above its expected range, with a $75 ...

Parabilis Medicines is developing a new type of peptide drug capable of hitting elusive disease targets inside cells. Cancer ...

Parabilis raised $670M via 33.5M shares at $20 and secured $75M Regeneron private placement at $18, totaling ~$745M gross proceeds ahead of Nasdaq listing. Helicon discovery platform engineers ...

In a target trial emulation using OneFlorida+ electronic health record data, GLP-1 receptor agonist use in adults with ...

June 4 (Reuters) - Biopharmaceutical company Parabilis Medicines said on Thursday it is aiming to raise as much as $475 ...

In today's Pharmaceutical Executive Daily, Parabilis Medicines prices a record-breaking $670 million IPO, Swedish biotech ...

Astronauts on long space missions may one day use plants to produce fresh stocks of medicines on demand, thanks to new ...